Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Bashinformsvyaz buys Lukoil stake in telecommunications JV

5/3/23 BISVP

Yandex will launch its own OpenYard servers this year

5/3/23 YNDX

Arsagera reported for 3 months of 2023 by RAS

5/3/23 ARSA

Tatneft reported for 3 months of 2023 by RAS

5/3/23 TATN

SPB Exchange summarized the results of trading in April

5/3/23 SPBE

AMD has reported for 3 months of 2023

5/3/23 AMD

Starbucks reported 6 months of fiscal year 2023

5/3/23 SBUX

Livent reported for 3 months of 2023

5/3/23 LTHM

Ford reported for 3 months of 2023

5/3/23 F

Sistema reported for 3 months of 2023 by RAS

5/2/23 AFKS